Does Tremfya List Joint Pain as a Side Effect?
Yes, Tremfya (guselkumab) can cause joint pain, including in patients using it primarily for skin conditions like plaque psoriasis. Clinical trials and post-marketing reports show arthralgia (joint pain) occurring in 1-3% of patients, similar to placebo rates in some studies but higher in others.[1][2] This holds even when the drug targets skin symptoms via IL-23 inhibition, as systemic effects can influence joints independently.
Why Might Joint Pain Happen During Skin Treatment?
Tremfya blocks IL-23, reducing inflammation in psoriasis, but immune modulation can trigger joint discomfort through unrelated pathways like localized inflammation or unmasking underlying issues (e.g., psoriatic arthritis). Paradoxical reactions—where anti-inflammatory drugs worsen specific symptoms—have been noted rarely with IL-23 inhibitors.[3] Patients with psoriasis often have subclinical joint involvement, so treatment might highlight rather than cause it.
How Common Is Joint Pain vs. Other Side Effects?
| Side Effect | Frequency in Psoriasis Trials |
|-------------|-------------------------------|
| Upper respiratory infections | 14-19% |
| Headache | 5-7% |
| Arthralgia (joint pain) | 1-3% |
| Fatigue | 1-2% |
| Diarrhea | 1-2% |
Joint pain ranks low but is reported across indications, including skin-focused use. In psoriasis studies (VOYAGE 1/2), it affected about 2% on Tremfya vs. 1% on placebo.[1][4]
What Should Patients Do If Joint Pain Starts?
Contact your doctor promptly—don't stop Tremfya without guidance, as abrupt halt risks psoriasis flare. They may assess for psoriatic arthritis (up to 30% of psoriasis patients develop it), adjust dose, or add pain relief like NSAIDs. Monitoring via blood tests or imaging helps rule out infection or other causes.[2]
How Does This Compare to Other Psoriasis Drugs?
Tremfya's joint pain risk is lower than TNF inhibitors like Humira (5-10% arthralgia) but similar to IL-17 blockers like Cosentyx (2-4%). Skyrizi (another IL-23 inhibitor) mirrors it at ~2%.[4][5] Switching drugs resolves symptoms in many cases.
Any Long-Term Data or Warnings?
Long-term extensions (up to 5 years) confirm joint pain remains infrequent and mostly mild/transient.[6] FDA label warns of hypersensitivity and infections but notes arthralgia under musculoskeletal effects. No black-box warnings specific to joints.[1]
[1]: Tremfya FDA Label
[2]: Janssen Tremfya Prescribing Information
[3]: Journal of the American Academy of Dermatology (paradoxical reactions review, 2022)
[4]: VOYAGE 1/2 Clinical Trial Data (NEJM, 2017)
[5]: Cosentyx/Skyrizi FDA Labels
[6]: Phase 3 Extension Studies (JAAD, 2021)